ResearchPod Summary
This systematic review provides a comprehensive global update on the prevalence of injecting drug use (IDU) and the health harms faced by people who inject drugs (PWID). By analyzing data from 2017 to 2022, the authors identified 14.8 million individuals who inject drugs across 190 countries, representing over 99% of the global population aged 15-64. The study goes beyond mere prevalence counts to characterize the social and environmental risks that exacerbate health crises among this population.
Researchers conducted a multi-stage systematic review, adhering to GATHER and PRISMA guidelines. They screened over 40,000 reports, incorporating peer-reviewed literature, grey literature, and data from international agencies. Key variables assessed included demographic characteristics (gender, age, sexuality), patterns of drug use, and exposure to structural risks such as homelessness, incarceration, and sex work. The team used meta-analyses to pool estimates for HIV, HBV, and HCV, as well as non-fatal overdose and other injecting-related diseases, providing a global and regional snapshot of the burden of disease.
The review reveals that HIV and hepatitis C remain highly prevalent among PWID, with an estimated 15.2% living with HIV and 38.8% having current HCV infection. Beyond these viruses, the findings highlight that 18.5% of PWID have experienced a recent non-fatal overdose, and 31.7% have suffered from recent skin or soft tissue infections. The data also illuminate the 'risk environment,' noting that nearly 60% of PWID have a history of incarceration and approximately 25% have experienced recent homelessness. These findings demonstrate that drug-related harm is deeply intertwined with broader social and economic vulnerabilities.
This study underscores that despite international goals to reduce blood-borne viruses and drug-related deaths, there have been no substantial improvements in the global burden of harm. The findings highlight an urgent need for scaled-up, evidence-based interventions like needle-syringe programs and opioid agonist treatment. Furthermore, the researchers argue that policy responses must move beyond individual behavioral change and instead address the structural, legal, and environmental factors—such as homelessness and the impacts of incarceration—that perpetuate these risks.
Sam: Reducing harm from injecting drugs takes more than changing how people inject. A global review finds widespread infections and other harms alongside high exposure to homelessness and incarceration. The authors argue that prevention needs to address those conditions, not just individual behaviour.
Alex: That makes this relevant beyond infection research. If you study housing, prisons, or access to healthcare, those conditions belong in the picture too. Whose review are we discussing?
Sam: It’s a global systematic review by Louisa Degenhardt and colleagues, published in The Lancet Global Health in 2023. For researchers and service planners, it broadens what needs measuring and what services need addressing. We’ll trace how they assembled the estimates, what the global averages conceal, and how far to trust the conclusions.
Alex: Before we get into the methods, what was missing from the earlier picture? Were infections getting attention while other harms were being overlooked?
Sam: The authors describe blood-borne viruses, infections transmitted through blood, as a major focus of research. But overdose, injecting-related infections, and mental health problems had received relatively limited global attention. Earlier global reviews from 2017 provided estimates of injecting and viral infections. This review updates those estimates and substantially widens the scope.
Alex: So the contribution isn’t simply a newer headcount. It’s also a different account of what researchers should be counting.
Sam: Yes. They include drug-use patterns, sexual behaviour, housing, arrest, incarceration, and involvement in sex work. They also expand evidence on gender and sexuality. Their organising idea is “risk environments”: the social, physical, economic, and political conditions that shape exposure to harm.
Alex: That’s a broad remit for a review. How did they gather evidence without relying only on countries that already have strong surveillance systems?
Sam: They searched academic databases and grey literature, meaning reports and material outside academic journals. They searched agency sources, contacted international organisations, and requested data from expert networks. There were no language restrictions. They screened about forty thousand papers and reports for the update, then combined eligible material with their earlier database.
AI-generated third-party summary by ResearchPod. Not official content or an endorsement by the paper authors or affiliated organizations.
Alex: That’s a count of records screened, not studies contributing to every estimate. What happened between finding a report and producing a country estimate?
Sam: Reviewers independently screened records and full texts, and extracted data were checked. For injecting prevalence, they graded estimates by the quality of the study method. Higher-quality estimates took priority, while the team also sought geographic coverage within countries. Comparable estimates could then be pooled.
Alex: Pooling can hide differences between studies. How did their approach handle that?
Sam: They used random-effects meta-analysis, which combines estimates while allowing underlying differences between studies. They built country estimates first, then weighted regional and global estimates using population information. They also carried uncertainty through calculations, rather than treating every input as a known value.
Alex: Can you give a concrete example where the choice of measurement changes what the estimate means?
Sam: Hepatitis C is a useful example. Antibodies indicate previous exposure, but they don’t establish that infection is still present. Hepatitis C RNA, the virus’s genetic material, indicates current infection. The authors used direct RNA estimates where available; elsewhere, they inferred current infection from antibody prevalence using an assumed clearance rate.
Alex: So “current infection” isn’t measured directly everywhere. That assumption matters when interpreting the global estimate.
Sam: It does. The authors also flag limited data on hepatitis C treatment uptake, which complicates estimating active infection. They argue the impact should be relatively small because countries where treatment likely made a sizable difference commonly had direct RNA measurements. That’s their assessment, not a reason to ignore the limitation.
Alex: With that distinction in place, what does the review say about the scale of injecting and its harms?
Sam: It estimates roughly fifteen million people globally injected drugs, among adults of working age. The uncertainty around that total is wide. Evidence of injecting exists across countries containing almost the entire global population, but far fewer countries have an estimate of how common it is.
Alex: Documenting that injecting occurs somewhere is different from measuring the population affected. What does the review estimate for infections among people who inject?
Sam: About one in six were estimated to be living with HIV. The burden varied considerably between regions and countries. For current hepatitis C infection, the global estimate was about four in ten.
Alex: Those averages convey a large burden. But if I’m planning services in one country, how misleading could the global profile be?
Sam: Quite misleading if treated as a local description. Opioids were generally the main drugs injected globally, but stimulants predominated in some countries. The authors highlight the Czech Republic and Puerto Rico as examples. That matters because evidence for effective interventions addressing dependent stimulant use is more limited than for opioids.
Alex: The drug profile changes the intervention options. And different injecting frequencies could change how much sterile equipment services need to provide.
Sam: The authors make that connection too. They also find substantial variation in syringe sharing and reuse. Their results argue against designing services around a single global model of injecting behaviour.
Alex: What does the wider lens add beyond infections and drug-use patterns?
Sam: Around six in ten people who inject drugs were estimated to have experienced incarceration during their lives. That’s lifetime exposure, not recent imprisonment. The review also documents substantial recent homelessness or unstable housing, with especially high estimated exposure in North America.
Alex: Those are associated risks, though. This review doesn’t isolate how much harm housing instability or incarceration causes, does it?
Sam: No. This is a synthesis of prevalence and exposure data, not a test of a structural intervention. The authors draw on evidence linking these environments with greater infection risk and poorer health. Their argument is that prevention planning must consider those conditions alongside individual behaviour.
Alex: And the health outcomes that usually receive less attention—did the review find enough evidence to say anything useful?
Sam: Available studies suggest substantial non-fatal overdose and mental health burdens. Around one in three were estimated to have had a recent skin or soft tissue infection. But coverage was uneven: depression and anxiety were assessed in only a small group of countries. High estimated burden and limited measurement coexist here.
Alex: Could we at least compare this review with its predecessor and judge whether prevention has improved?
Sam: Not cleanly. The authors report no substantial overall reductions in injecting prevalence or the major viral harms compared with the earlier review. But they repeatedly warn that changing study methods obstruct direct comparisons. A changed estimate can reflect changed measurement rather than a changed population.
Alex: So this is stronger as a map of burden and evidence gaps than as a clean time trend.
Sam: That’s my reading. Its breadth and systematic searching are strengths. But injecting is stigmatised and poorly captured by ordinary population surveys, so estimates often depend on indirect methods or targeted surveys. Those can be biased, and many countries lack regular updates. The review cannot make uneven source evidence uniformly reliable.
Alex: Given those limits, who should read the full document, and where should they start?
Sam: Researchers in addiction, infectious disease, surveillance, and harm reduction should read it. Start with the methods for selecting and pooling country estimates, then the country-level appendices relevant to your setting. Read the implications section for its argument about environmental risks. For everyone else, remember this: preventing injecting-related harm means addressing the conditions people live in, not only how they inject.
Alex: Thanks for listening.